Shay Capital’s Sagimet Biosciences SGMT Stock Holding History

Shay Capital’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19,332	Closed	-$87K	–	409
2024 Q4	$87K	Buy	+19,332	New	+$97.9K	0.01%	282

Other funds holding SGMT

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Shay Capital's SGMT Position: Q1 2025 in Review

Shay Capital sold out of Sagimet Biosciences (SGMT) in Q1 2025, closing a stake of 19,332 shares — an estimated $87K sold.

Shay Capital first reported a position in SGMT in Q4 2024 and held it in 1 quarter. The position peaked at $87K in Q4 2024. 70 funds tracked by Wall St. Rank hold SGMT as of Q1 2025.

Shay Capital reported no remaining Sagimet Biosciences position as of Q1 2025 after selling out during the quarter.
Shay Capital sold 19,332 Sagimet Biosciences shares in Q1 2025, an estimated $87K.
Shay Capital first reported a position in Sagimet Biosciences in Q4 2024 and held it in 1 quarter.
Shay Capital's Sagimet Biosciences position peaked at $87K in Q4 2024.
70 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2025.

Based on Shay Capital's 13F filing for Q1 2025, filed 15 May 2025.